Presepsin as a diagnostic biomarker of sepsis in patients with sepsis associated acute kidney injury: a systematic review and meta-analysis
acute kidney injury, sepsis, presepsin, meta-analysis, diagnosis
“Introduction: the early diagnosis of sepsis impacts on morbidity and mortality, and depends on the use of clinical and laboratory criteria. In this context, biomarkers play a fundamental role and should have a similar cure in different clinical situations associated with sepsis. Objective: to evaluate the effectiveness of presepsin as a biomarker for diagnosing sepsis in patients with sepsis associated acute renal injury. Methods: a comprehensive search was carried out in PubMed (National Library of Medicine), Web of Science and Scopus databases between 2010 and 2023. The PEO strategy (population, exposure and outcome) was used, using the keywords “acute Kidney Injury”, “sepsis” and “presepsin”. The diagnostic accuracy of PSP will be compared in both groups, using statistical analysis. Results: a total of 22 studies were identified in the databases, and 3 studies were selected for analysis (meta-analysis). The PSP standardized mean was higher in the sepsis group when compared to the non-sepsis group, SMD (95% CI) 1.6067 (0.9369-2.2766), p 0.0047. Conclusion: PSP is an effective sepsis diagnostic biomarker in patients with sepsis-associated acute kidney injury.”